MIT research shows positive results of skin patch for cancer treatment

By Nikita Chaurasia  Date: 2019-08-26

MIT research shows positive results of skin patch for cancer treatment
  • The skin patch designed, demonstrated positive results in an experiment on mice and human skin samples.
  • The MIT researchers designed the patch to fight melanoma cancer.

Researchers at the Massachusetts Institute of Technology reportedly announced successful results of a skin patch developed to offer cancer treatment in mice & human skin samples at the American Chemical Society conference in California, San Diego.

Apparently, the researchers at the MIT designed the patch to fight melanoma, a fatal but treatable skin cancer. For the uninitiated, Melanoma is subjected to be caused by an extreme exposure to UV rays from the sun or other sources. It has been claimed that the patch is less than a centimeter long and covered with a gluey film, which allows it to be applied and detached from the skin within a minute.

As per trusted reports, the researchers of the organization used the patch to deliver a toxin in healthy mice and later compared the immune response to other treatment methods used to vaccinate against the flu and measles. The results of the skin patch presented a robust antibody response along with a strong immune response in human skin.

The lead author of the study and HOD of Chemical Engineering, MIT, Dr. Paula Hammond reportedly stated that the organization’s recently designed patch technology can be used to offer vaccines to fight against various infectious diseases. Additionally, the researchers are pleased by the possibility of the patch to win against melanoma cancer.

The patch is embedded with microneedles, developed through a layer-by-layer coating process. This provides the advantage over syringes for its painless, easy to administer and reduced infection risk characteristics.

The researchers claimed that the patch treatment produced over 9 times the level of infection-fighting antibodies while comparing to the intramuscular injections. Additionally, it also produced over 160 times the level of antibodies compared to subcutaneous injections.

Speculation has it that the research was aided by the U.S. Department of Defense along with the Koch Institute for Integrative Cancer Research at MIT and Singapore-MIT Alliance for Research and Technology.

Source credit: https://www.cnbc.com/2019/08/25/new-skin-patch-to-deliver-cancer-medicine-shows-promise-in-mice-mit-scientists-say.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...